Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Firebrick Pharma Limited ( (AU:FRE) ) is now available.
Firebrick Pharma has confirmed that the registration process for its Nasodine Nasal Spray in the Philippines has advanced, with the country’s Food and Drug Administration accepting the product dossier following pre-assessment and commencing a formal review expected to take at least six months. The move marks a key step toward potential 2026 approval in a large pharmaceutical market where Firebrick is partnered with and partly backed by SV More Pharma, and benefits from a regulatory pathway that treats Nasodine as a disinfectant spray manufactured locally, allowing submission based on a manufacturing dossier without requiring clinical efficacy studies.
The most recent analyst rating on (AU:FRE) stock is a Hold with a A$0.05 price target. To see the full list of analyst forecasts on Firebrick Pharma Limited stock, see the AU:FRE Stock Forecast page.
More about Firebrick Pharma Limited
Firebrick Pharma Limited is an Australian pharmaceutical company focused on developing and commercialising novel formulations and uses of povidone-iodine (PVP-I). Its lead product is Nasodine Nasal Spray (0.5% PVP-I), already introduced in the United States, Singapore and Fiji & the South Pacific, and the company is expanding its portfolio with Nasodine Throat Spray as a convenient alternative to traditional PVP-I throat gargles.
Average Trading Volume: 123,122
Technical Sentiment Signal: Buy
Current Market Cap: A$16.6M
See more insights into FRE stock on TipRanks’ Stock Analysis page.